A randomized, double-blind, placebo-controlled trial looked at patients with moderately severe Crohn’s disease who were in remission following steroid therapies. After a one-year follow-up, 47.5 percent of patients taking the probiotic and 53.2 percent in the placebo group had relapsed.
More Articles on Gastroenterology:
Carilion Clinic Gastroenterology Adds Four Specialists, Creates Fellowship Program
FDA Supports CT Colonography Screenings for Colon Cancer Prevention
Dr. Dennis Ng Joins Ferrell-Duncan Clinic as Gastroenterologist
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.